Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial

Published:2019-05 Issue:5 Volume:7 Page:356-367
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Zinman Bernard,Bhosekar Vaishali,Busch Robert,Holst Ingrid,Ludvik Bernhard,Thielke Desirée,Thrasher James,Woo Vincent,Philis-Tsimikas Athena

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference26 articles.

1. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Davies;Diabetes Care,2018

2. Introduction: standards of medical care in diabetes—2019;Diabetes Care,2019

3. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes;Marso;N Engl J Med,2016

4. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

5. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017

Cited by 235 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Semaglutide for the management of diabesity: The real-world experience;World Journal of Methodology;2024-09-20

2. Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes;Journal of the American College of Cardiology;2024-09

3. Real‐world safety profile of once‐weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real‐world Evidence (SURE) programme;Diabetes, Obesity and Metabolism;2024-08-08

4. Lipid lowering effects of incretin-based therapies, relevant for cardiovascular benefit?;Current Opinion in Lipidology;2024-07-30

5. Evaluating the safety profile of semaglutide: an updated meta-analysis;Current Medical Research and Opinion;2024-07-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3